Signum US Healthcare works to bring Cyberknife® technology to China. Cyberknife radiation treatment represents a major advance in cancer treatment. Through a partnership with Chinese health care providers, Signum hopes to make the device available to patients in China. Cyberknife attacks a tumor using radiation in order to inhibit or kill rapidly dividing cells. The machine delivers the radiation from many angles so that the tumor receives large doses of radiation while the surrounding healthy tissue receives much smaller doses. In the past, this technology was only available to treat brain tumors, but the Cyberknife makes it possible to treat tumors in any part of the body.
Why are multiple small beams of radiation more effective than a single, concentrated beam? A specific concentration of radiation is needed to destroy a tumor. The radiation must pass through healthy cells to reach the cancer cells. If all of the radiation is delivered from a single point, healthy cells as well as cancerous cells will be blasted with lethal doses.
However, if the radiation device aims at the tumor from ten different points, and each beam contains 1/10th of the necessary radiation, then the tumor will still be given a full dose, but the healthy tissue around the tumor will only receive 1/10th of a lethal dose. Using Cyberknife technology to direct the radiation treatment means that fewer healthy cells die and that the patient experiences milder side effects from the radiation treatment.
Cyberknife technology is already available at many sites in the continental United States. Currently there are about 10 facilities in China that provide Cyberknife technology.
About the Author: Steven Pinkert serves as the Chairman of the Board for Signum US Healthcare, Inc. Pinkert practices as a lawyer at Pinkert & Marsh, P.A., and possesses both a JD and an MD.